Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 17/20 | 1.00 |
| ▸ | CHUK | O15111 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124681 | 0.96 | KIF11 (0.92) | KIF11CHUKKMT2A | |
| SCHEMBL4137905 | 0.95 | KIF11 (0.90) | KIF11CHUKKDM4EMTNR1AMTNR1B | |
| SCHEMBL4132335 | 0.93 | KIF11 (1.00) | KIF11KMT2A | |
| SCHEMBL4126195 | 0.87 | KIF11 (0.77) | KIF11CHUK | |
| SCHEMBL4137772 | 0.80 | KIF11 (0.75) | KIF11 | |
| SCHEMBL4138086 | 0.79 | KIF11 (0.65) | KIF11CHUK | |
| SCHEMBL4129948 | 0.76 | KIF11 (0.62) | KIF11CHUK | |
| SCHEMBL26406089 | 0.75 | KIF11 (0.70) | KIF11KDM4EMTNR1AMTNR1BKMT2A | |
| SCHEMBL4137834 | 0.75 | KIF11 (0.60) | KIF11CHUKKDM4E | |
| SCHEMBL3219090 | 0.75 | KIF11 (0.64) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170882-A1 | Methods and compositions | CYTOKINETICS, INCORPORATED | 2009-07-02 | — | — | US | claimed |
| EP-1771176-A2 | METHODS AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-11 | — | — | EP | claimed |
| WO-2006005063-A2 | METHODS AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-12 | — | — | WO | claimed |
| US-20090170882-A1 | Methods and compositions | CYTOKINETICS, INCORPORATED | 2009-07-02 | — | — | US | disclosed |
| US-20090170882-A1 | Methods and compositions | CYTOKINETICS, INCORPORATED | 2009-07-02 | — | — | US | disclosed |
| US-20090170882-A1 | Methods and compositions | CYTOKINETICS, INCORPORATED | 2009-07-02 | — | — | US | disclosed |
| EP-1771176-A2 | METHODS AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006005063-A2 | METHODS AND COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170882-A1 | Methods and compositions | KIF5B, KIF5C, KIF2C | KIF11 10/4885CHUK 3598/4885KDM4E 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.